Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 1001 - 1050 of 4862 results
- Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
- A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats.
- Protective effect of nitric oxide on ischemia/reperfusion-induced renal injury and endothelin-1 overproduction.
- Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
- HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
- Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity.
- The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension.
- In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction.
- Protective mechanisms of inosine in platelet activation and cerebral ischemic damage.
- Genetic deletion or antibody blockade of alpha1beta1 integrin induces a stable plaque phenotype in ApoE-/- mice.
- Important role of apoptosis signal-regulating kinase 1 in ischemia-induced angiogenesis.
- Development of a multicenter peripheral arterial interventional database: the PVD-QI2.
- Effect of clopidogrel plus aspirin on tissue perfusion and coronary flow in patients with ST-segment elevation myocardial infarction: a new reperfusion strategy.
- Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee.
- Evaluation of coronary artery patency using cardiac markers.
- Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial.
- Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy.
- Calpain inhibitor A-558693 in experimental focal cerebral ischemia in rats.
- Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.
- Hypoxia-inducible factor-1alpha DNA induced angiogenesis in a rat cerebral ischemia model.
- Early administration of a second-generation perfluorochemical decreases ischemic brain damage in a model of permanent middle cerebral artery occlusion in the rat.
- Evaluating the effect on patient outcomes of appropriate and inappropriate use of beta-blockers as secondary prevention after myocardial infarction in a medicaid population.
- SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.
- Predictive models for hERG potassium channel blockers.
- Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
- Identification of a novel calpain inhibitor using phage display.
- Anti-angiogenic effect of an insertional fusion protein of human basic fibroblast growth factor and ribonuclease-1.
- Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension.
- Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2.
- Effects of Nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study.
- A novel human CD32 mAb blocks experimental immune haemolytic anaemia in FcgammaRIIA transgenic mice.
- Gene expression profiling of human atrial myocardium with atrial fibrillation by DNA microarray analysis.
- Oral vitamin C administration reduces early recurrence rates after electrical cardioversion of persistent atrial fibrillation and attenuates associated inflammation.
- Early inhibition of caspase-3 activity lessens the development of graft coronary artery disease.
- Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1.
- 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: the successful reduction of hERG activity. Part 2.
- Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.
- Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.
- Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
- Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
- Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.
- Pyruvate modulates hepatic mitochondrial functions and reduces apoptosis indicators during hemorrhagic shock in rats.
- Effects of platelet-activating factor on nitrergic transmission in rabbit corpus cavernosum.
- Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury.
- Monocyte suppressing action of fenofibrate.
- The changing epidemiology of diabetic microangiopathy in type 1 diabetes.
- Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure.
- Daclizumab to prevent rejection after cardiac transplantation.
- Rapid alterations in transferrin sialylation during sepsis.
- Rho-associated kinase modulates myocardial inflammatory cytokine responses.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >